NEWS

Pharmaceutical Industry news helps our clients to give competitive edge to their customers and also latest pharmaceutical industry news assists them in gaining updated knowledge. We bring you Global Pharmaceutical news about acquisitions, project undertakings, business and marketing, subjects, and industry related subjects, written in a professional, unbiased and thought-provoking format. Our international pharmaceutical News will help you enhance your business knowledge and productivity.

U.S. regulators have proposed lowering the bar for clinical trial success for experimental Alzheimer’s drugs to better align with the current emphasis on the need to treat people when they are in the earliest stages of the brain-wasting disease. Medicines tested to treat Alzheimer’s have had a dismal track record,…

Merck KGaA and Pfizer’s cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said. The results revealed on Thursday mark another setback for a drug that is a late starter in the rapidly evolving field of cancer immunotherapies.…

Bayer said it had received a warning letter from the U.S. Food and Drug Administration over how it handled production of some drugs at its Leverkusen, Germany headquarters. The German drugmaker, which is taking over U.S. seed maker Monsanto, is addressing the FDA’s complaints regarding manufacturing practices, which stem from…

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson’s Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy. The drug is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, the regulator said. (bit.ly/2F072ih) The approval comes…

Merck & Co Inc on Tuesday said it will end another late-stage trial of an Alzheimer’s drug because it was unlikely to work, adding to the pile-up of failures to find an effective treatment for the mind-wasting disease. The company was testing the drug, Verubecestat, in patients with very early,…

Novartis’s Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market. The U.S. Food and Drug Administration (FDA) approved a 40 milligrams per milliliter injection of the…

PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today launched its Biological Sample Lifecycle Management service, enabling optimal use of human biological samples. The new service enables biopharmaceutical clients to more efficiently manage their often irreplaceable patient biological sample assets from informed consent and collection at site, through…

Novartis’s Sandoz division said on Tuesday it has won approval in the United States for a larger dosage of its Glatopa treatment for multiple sclerosis patients. The Food and Drugs Administration has approved the use of 40 milligrams per milliliter injection, taken three times per week, as a fully suitable…

North China Pharmaceutical Co Ltd Says it received goods manufacture practice (GMP) certificate from Hebei Food and Drug Administration. Certificate issued tablets and hard capsules production line manufactured by the company and the valid period is until Jan. 17, 2023.   Source: reuters.com

Britain’s healthcare watchdog (NICE) recommended Roche’s medicine Gazyvaro for previously untreated advanced follicular lymphoma patients after initially rejecting the Swiss drugmaker’s medicine last year as too expensive. NICE recommended Gazyvaro, also called Gazyva, for use by the National Health Service (NHS) with chemotherapy in patients with higher risk of relapse.…

loadmore..